Assembly Biosciences, Inc.
NasdaqGS ASMB
Assembly Biosciences, Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -163.94%
-
Assembly Biosciences, Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -1,497.97%, a -2,221.35% change year over year.
-
Assembly Biosciences, Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was -64.53%, a 90.28% change year over year.
| Date | EBIT Margin | EPS (Basic) | EPS (Diluted) | Shares (Basic, Weighted) |
|---|
| CEO | Mr. Jason A. Okazaki |
| IPO Date | Dec. 17, 2010 |
| Location | United States |
| Headquarters | 331 Oyster Point Boulevard |
| Employees | 65 |
| Sector | Health Care |
| Industries | |
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Past 5 years
USD 20.03
USD 0.84
USD 2.59
StockViz Staff
January 15, 2025
Any question? Send us an email